Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

Bioxytran secures UAE Free Sale Certificate for A-SUQAR, targeting high-diabetes Gulf markets.

What the company is saying

Bioxytran, Inc. (OTCQB:BIXT) announces that its A-SUQAR tablet has obtained a government-issued Free Sale Certificate, legalized by the issuing country's Ministry of Foreign Affairs and prepared for attestation for use in the United Arab Emirates. The company frames this as a key regulatory milestone, enabling product registration and market entry in the UAE and the wider Gulf Cooperation Council region. The announcement emphasizes the severe diabetes burden in the Gulf, citing International Diabetes Federation data: 1.27 million adults with diabetes in the UAE (20.7% prevalence, 64% undiagnosed), 5.34 million in Saudi Arabia (23.1% prevalence, projected to reach 9.5 million by 2050), and 908,500 in Kuwait (25.6% prevalence), totaling 7.5 million adults across these three countries. Bioxytran highlights A-SUQAR’s non-systemic, digestive-tract mechanism and positions the product as a complement to diet and exercise. CEO David Platt, Ph.D., states that the certificate is a critical step toward commercialization in the UAE and neighboring markets. The company discloses that A-SUQAR is regulated as a dietary supplement in the United States, with structure and function claims supported by FDA safety information, but clarifies that the FDA does not approve such supplements before marketing. The tone is confident and opportunity-focused, but the announcement does not mention sales, revenues, or commercial agreements.

What the data suggests

The announcement provides detailed epidemiological data: 1.27 million adults with diabetes in the UAE (20.7% prevalence, 64% undiagnosed), 5.34 million in Saudi Arabia (23.1% prevalence, projected to reach 9.5 million by 2050), and 908,500 in Kuwait (25.6% prevalence), for a combined 7.5 million adults in these three countries. Across the Middle East and North Africa region, 84.7 million adults were living with diabetes in 2024, expected to grow by 92% to 162.6 million by 2050. The Free Sale Certificate is a regulatory prerequisite for product registration but does not itself confer market access or guarantee sales. No financial, operational, or sales figures for Bioxytran or A-SUQAR are disclosed. The company’s next steps are to proceed with product registration in the UAE and evaluate registration pathways in Saudi Arabia, Kuwait, and other GCC markets. The only realized milestone is the receipt of the Free Sale Certificate; all commercial outcomes remain forward-looking and contingent on local regulatory approvals.

Analysis

The announcement's tone is positive and emphasizes the regulatory milestone of receiving a Free Sale Certificate for A-SUQAR® in the UAE, which is a necessary step for market entry but does not equate to commercial launch or revenue generation. The majority of the claims are factual and relate to regulatory progress, product characteristics, and regional diabetes prevalence, but the narrative leans heavily on the large addressable market and future intentions to register and launch in multiple Gulf markets. No financial, sales, or profitability data are disclosed, and there is no timeline for when commercial benefits might be realized. The use of epidemiological statistics inflates the perceived opportunity without evidence of market penetration or demand. The announcement does not mention any large capital outlay or immediate earnings impact, so the capital intensity flag is false. Overall, the gap between narrative and evidence is moderate: the regulatory milestone is real, but the commercial and financial impact remains unproven and undated.

Risk flags

• ●Regulatory execution risk remains high: while the Free Sale Certificate is a prerequisite, actual product registration and approval for sale in the UAE and other Gulf markets require further regulatory steps, each with uncertain timing and outcome.
• ●Commercialization risk is significant: no distribution agreements, launch dates, or sales channels are disclosed, so there is no evidence of market access or demand beyond regulatory intentions.
• ●Market adoption risk is material: although the diabetes prevalence in the region is high, the announcement provides no clinical efficacy data, pricing, reimbursement status, or competitive positioning for A-SUQAR, making actual uptake and revenue potential uncertain.

Bottom line

Bioxytran’s announcement of a Free Sale Certificate for A-SUQAR in the UAE is a regulatory milestone, not a commercial breakthrough. The company is targeting a region with 7.5 million adults with diabetes across the UAE, Saudi Arabia, and Kuwait, but has not yet secured product registration, distribution, or sales in any Gulf market. No financial or operational metrics are disclosed, and all commercial outcomes remain contingent on further regulatory approvals. Investors should focus on whether Bioxytran can translate this regulatory progress into actual product launches, sales agreements, and revenue. The most important takeaway is that while the addressable market is large, the pathway to monetization is still at an early stage and unproven.

Announcement summary

(OTCQB:BIXT) Bioxytran, Inc. announced that its A-SUQAR® tablet has received a government-issued Free Sale Certificate, legalized by the issuing country's Ministry of Foreign Affairs and prepared for attestation for use in the United Arab Emirates. The certification confirms that A-SUQAR® is lawfully manufactured and freely sold as a food and health supplement, serving as a key regulatory document for product registration and market entry in the UAE and the wider Gulf Cooperation Council (GCC) region. According to the International Diabetes Federation (IDF) Diabetes Atlas, 11th Edition (2025), approximately 1.27 million adults in the United Arab Emirates are living with diabetes, with an age-standardized prevalence of 20.7%, and an estimated 64% of those cases undiagnosed. In Saudi Arabia, approximately 5.34 million adults are living with diabetes (age-standardized prevalence 23.1%), a figure projected to rise to 9.5 million by 2050. Kuwait has approximately 908,500 adults living with diabetes (age-standardized prevalence 25.6%), giving it one of the highest diabetes prevalence rates in the world. Together, these three countries account for roughly 7.5 million adults with diabetes. Across the IDF Middle East and North Africa (MENA) region, 84.7 million adults were living with diabetes in 2024, a number expected to grow by 92% to 162.6 million by 2050. The region has the highest diabetes prevalence of any IDF region, and about one in three adults with diabetes have not been diagnosed. A-SUQAR® is a chewable tablet taken before meals, designed to slow the activity of intestinal enzymes that break down dietary carbohydrates into glucose, thereby supporting healthier post-meal blood sugar levels. The product is built on Bioxytran's proprietary polysaccharides technology and acts locally in the digestive tract rather than systemically. David Platt, Ph.D., Chief Executive Officer of Bioxytran, stated that securing the attested Free Sale Certificate is an important step toward bringing A-SUQAR® to consumers in the UAE and neighboring markets. With the attested Free Sale Certificate, Bioxytran and its commercial distribution partner intend to proceed with product registration in the UAE and evaluate registration pathways in Saudi Arabia, Kuwait, and other GCC markets. Timing for commercial launch in each market will depend on the completion of local regulatory requirements. In the United States, A-SUQAR® is regulated as a dietary supplement and is in compliance with U.S. dietary supplement requirements. The product has structure and function claims and supporting safety information by the U.S. Food and Drug Administration (FDA), but the FDA does not approve dietary supplements or their structure/function claims before they are marketed. Bioxytran's lead drug candidate, ProLectin-M, is being developed as a broad-spectrum antiviral.

Disagree with this article?